Fasikl developed Felix NeuroAI™ Wristband, the first FDA-cleared AI therapeutic specifically authorized for essential tremor. This intelligent, 100% noninvasive prescription wearable delivers individually calibrated peripheral neuromodulation to reduce upper-limb hand tremor and restore daily independence for adults worldwide.
Built upon more than two decades of foundational R&D in neural engineering, computational neuroscience, and deep learning models, Fasikl bridges human biology and artificial intelligence to establish a scalable standard in bioelectronic medicine.
Our proprietary closed-loop Neuro-AI platform combines clinical rigors with scalable software infrastructure to address multi-billion dollar markets in neurological care.
Validated through a double-blind, randomized, sham-controlled clinical trial — the highest standard in medical science. Patients receiving Felix experienced statistically significant, lasting improvements in hand tremor symptoms and upper-limb functional mobility compared to sham controls.
Our core neural decoding engines and cloud-based AI infrastructure support rapid expansion beyond essential tremor into broader movement disorders, neurorehabilitation, and bioelectronic therapeutics without hardware redesigns.
Fasikl is a global pioneer capable of recording human peripheral nerve activity at single-fiber resolution while simultaneously delivering targeted neural stimulation. Real-time neural decoding models enable dynamic, patient-specific calibration.
Tested with human amputees, our bidirectional nerve-computer interface establishes intuitive, high-degree-of-freedom robotic control directly from voluntary neural intent — opening future pipelines in prosthetics and motor restoration.
We combine rigorous clinical compliance, comprehensive intellectual property protection, and patient-first design to deliver safe, effective, noninvasive alternatives to brain surgery and pharmacological side effects.
Backed by 20+ years of institutional neural engineering expertise, Fasikl is defining the future where artificial intelligence seamlessly integrates with the peripheral nervous system to manage neurological diseases continuously.
Fasikl engages institutional investors, healthcare funds, neurological centers, and international distribution leadership to scale Neuro-AI therapeutics worldwide.
Backed by proprietary multi-channel sensor designs, closed-loop neural decoding algorithms, and cloud calibration patents that protect our technology across major global healthcare markets.
Founded and led by recognized leaders in neuroengineering, bioelectronics, and artificial intelligence, including CEO Dr. Zhi Yang, with deep academic and commercial track records in neural interfaces.
Commercialization efforts focus on neurologist prescription workflows, insurance reimbursement pathways, movement disorder center partnerships, and international regulatory authorizations.
Patient device data feeds back into HIPAA-compliant, encrypted cloud AI models, driving continuously refining therapeutic logic and actionable real-world evidence for clinical care teams.
